-
12:11:05 PM

TEVA Stock News

03/13/23 9:33 AM
NYSE : TEVA
Teva Announces Early Tender Results of its Debt Tender Offer, Increases to Tender Caps and Election of Early Settlement
7.125% Senior Notes due 2025, CUSIP 88167 AAN1/ ISIN US88167AAN19, CUSIP 88167 A AM3/ ISIN US88167AAM36, CUSIP N8540W AC8/ ISIN USN8540WAC84, issued by Teva Pharmaceutical Finance Netherlands III B.V.; 6.000% Senior Notes due 2025, Common Code 219821395/ ISIN XS2198213956, Common Code 208396323/ ISIN XS2083963236, Common Code 208396269/ ISIN XS2083962691...
RHEA-AI
neutral
03/01/23 4:11 PM
NYSE : TEVA
Teva Announces Successful Upsize and Pricing of $2,490,000,000 (equivalent) Sustainability-Linked Senior Notes and the Increase of the Maximum Tender Amount of its Debt Tender Offer
Teva Pharmaceutical Industries Ltd. announced today that it successfully upsized its offering and priced approximately $2,490,000,000 of its sustainability-linked senior notes. The principal amount of the offering was increased from the previously announced offering size of $2,060,000,000 and the maximum tender amount of Teva’ s previously...
RHEA-AI
neutral
02/23/23 8:00 AM
NYSE : TEVA
Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ Lives
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., today announced the print publication of the IMPACT-TD Scale, an easy-to-use, standardized and clinician-rated assessment. Yet, current clinical evaluation practices focus mainly on the severity of TD movements,” said Richard Jackson, MD, Assistant...
RHEA-AI
neutral
02/17/23 4:56 PM
NYSE : TEVA
fda approval
Teva Announces FDA Approval of AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, a New Once-Daily Formulation of AUSTEDO® (deutetrabenazine) Tablets
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., today announced that the U.S. Food and Drug Administration has approved AUSTEDO XR extended-release tablets, a new once-daily formulation indicated in adults for tardive dyskinesia and chorea associated with Huntington’ s disease.
RHEA-AI
positive